<div id="readability-page-1"><p>Invesco Ltd. raised its position in  Abbott Laboratories (NYSE:ABT - Free Report) by 51.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The institutional investor  owned 13,951,907 shares of the healthcare product maker's stock after acquiring an additional 4,713,135 shares during the period. Invesco Ltd. owned approximately 0.80% of Abbott Laboratories worth $1,868,718,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p><div><p><span></span><span>Get <strong>Abbott Laboratories</strong> alerts:</span></p></div><ul><li>AbbVie’s Prognosis: The February Dip Looks Like a Buy Signal</li></ul><p>Other large investors have also made changes to their positions in the company. Seven Mile Advisory lifted its holdings in shares of  Abbott Laboratories by 40.8% during the 3rd quarter. Seven Mile Advisory now owns 5,587 shares of the healthcare product maker's stock valued at $748,000 after purchasing an additional 1,620 shares during the last quarter.  Employees Retirement System of Texas acquired a new stake in shares of  Abbott Laboratories in the 3rd quarter worth $2,150,000.  Douglass Winthrop Advisors LLC grew its stake in  Abbott Laboratories by 8.1% during the 3rd quarter. Douglass Winthrop Advisors LLC now owns 45,198 shares of the healthcare product maker's stock worth $6,054,000 after buying an additional 3,395 shares during the last quarter.  BOKF NA increased its position in  Abbott Laboratories by 3.6% during the 3rd quarter. BOKF NA now owns 140,308 shares of the healthcare product maker's stock valued at $18,793,000 after buying an additional 4,822 shares in the last quarter.  Finally, RD Lewis Holdings Inc. raised its stake in  Abbott Laboratories by 4.7% in the third quarter. RD Lewis Holdings Inc. now owns 11,852 shares of the healthcare product maker's stock valued at $1,527,000 after buying an additional 530 shares during the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds. </p><h2>Analyst Upgrades and Downgrades</h2><p>Several equities research analysts have weighed in on the company. BTIG Research lowered their price target on Abbott Laboratories from $145.00 to $140.00 and set a &#34;buy&#34; rating for the company in a report on Tuesday, February 17th. Leerink Partners decreased their price objective on shares of Abbott Laboratories from $136.00 to $119.00 and set a &#34;market perform&#34; rating for the company in a research report on Friday, January 30th. William Blair upgraded shares of Abbott Laboratories to a &#34;strong-buy&#34; rating in a research note on Thursday, November 20th. Oppenheimer dropped their target price on shares of Abbott Laboratories from $140.00 to $132.00 and set an &#34;outperform&#34; rating on the stock in a research report on Friday, January 23rd. Finally, Royal Bank Of Canada decreased their price target on shares of Abbott Laboratories from $147.00 to $135.00 and set an &#34;outperform&#34; rating for the company in a report on Friday, January 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued  a Buy rating and four have issued  a Hold rating to the company's stock. Based on data from MarketBeat, the company  has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $136.16.</p><ul><li>Is Abbott’s January Pullback a Good Time to Buy? </li></ul><p><b>Check Out Our Latest Analysis on ABT</b></p><h2>Abbott Laboratories News Summary</h2><p>Here are the key news stories impacting Abbott Laboratories this week:</p><ul>   <li><span>Positive Sentiment: </span>New clinical evidence — The FreeDM2 randomized trial showed FreeStyle Libre continuous glucose monitoring produced meaningful improvements in HbA1c and more time-in-range for people with Type 2 diabetes on basal insulin, supporting adoption and longer-term revenue upside for Abbott’s diabetes business. <i></i><span>Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management</span></li>    <li><span>Positive Sentiment: </span>Brand/consumer engagement — Abbott relaunched its “Abbott Dream Team” program with Real Madrid, a marketing push that can boost awareness for consumer-facing segments (nutrition, diagnostics) and strengthen long-term end-market demand. <i></i><span>Abbott and Real Madrid launch nationwide effort to build the next 'Abbott Dream Team'</span></li>    <li><span>Positive Sentiment: </span>Value narrative — Analyst commentary and stock-screen mentions (Zacks, dividend-aristocrat lists) emphasize ABT’s defensive characteristics, dividend safety and long-term value, which can support investor demand despite near-term noise. <i></i><span>Why Abbott (ABT) is a Top Value Stock for the Long-Term</span></li>    <li><span>Neutral Sentiment: </span>Analyst views diverging — Coverage shows only small shifts in modeled fair value overall, but several analysts are revising targets and re-weighting execution risk vs. long-run growth; this creates mixed signals and short-term volatility. <i></i><span>How The Story On Abbott Laboratories (ABT) Is Shifting As Analysts Rework Targets And Risks</span></li>    <li><span>Negative Sentiment: </span>Near-term earnings reception — Q4 revenue came in below consensus while EPS roughly met estimates, and sector Q4 comparisons flagged pockets of weakness; that revenue miss likely pressured the stock. <i></i><span>Q4 Earnings Highs And Lows: Abbott Laboratories <span>NYSE: ABT<span></span></span> Vs The Rest Of The Medical Devices &amp; Supplies - Diversified Stocks</span></li>    <li><span>Negative Sentiment: </span>Price-target actions — Citigroup trimmed its price target slightly (from $140 to $136) while keeping a buy rating; small cuts across some desks add downward pressure even if sentiment remains constructive. <i></i><span>Benzinga: Citigroup price target cut</span></li> </ul><h2>Abbott Laboratories Stock Performance</h2><ul><li>2 Healthcare Names That Could Get a Big Boost From Earnings</li></ul><p>ABT opened at $108.18 on Friday. The firm has a fifty day moving average price of $114.91 and a 200 day moving average price of $124.08. Abbott Laboratories has a 1 year low of $105.27 and a 1 year high of $139.06. The stock has a market cap of $187.98 billion, a P/E ratio of 29.08, a P/E/G ratio of 1.75 and a beta of 0.74. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. </p><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting the consensus estimate of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The company had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. During the same quarter last year, the business earned $1.34 earnings per share. The firm's revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS.  Equities research analysts anticipate that  Abbott Laboratories will post 5.14 earnings per share for the current year. </p><h2>Abbott Laboratories Dividend Announcement</h2><p>The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a dividend of $0.63 per share. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. Abbott Laboratories's dividend payout ratio (DPR) is 67.74%. </p><h2>Insider Transactions at Abbott Laboratories</h2><p>In related news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the company's stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $102,288.30. Following the completion of the transaction, the executive vice president owned 146,377 shares of the company's stock, valued at approximately $16,918,253.66. This represents a 0.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Mary K. Moreland sold 613 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $70,850.54. Following the transaction, the executive vice president owned 104,291 shares in the company, valued at $12,053,953.78. This represents a 0.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 3,055 shares of company stock worth $353,097 over the last quarter. Company insiders own  0.46% of the company's stock. </p><h2>Abbott Laboratories Company Profile</h2> (Free Report)<p>Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.  </p><p>In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Abbott Laboratories</li><li>The gold chart Wall Street is terrified of…</li><li>Elon Musk already made me a “wealthy man”</li><li>Unlocked: Elon Musk’s Next Big IPO</li><li>Silver paying 20% dividend. Plus 68% share gains</li><li>1,500 Banks Just Handed the Fed Your Bank Account</li></ul><p><strong>Want to see what other hedge funds are holding ABT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2><p>Before you consider Abbott Laboratories, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p><p>While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Invesco Ltd. increased its stake in Abbott Laboratories by 51% in Q3, owning 13,951,907 shares valued at approximately $1.87 billion. Other investors also raised their positions, with 75.18% of the stock held by institutional investors. Analysts have mixed views on Abbott, with price targets ranging from $119 to $140, and a consensus rating of "Moderate Buy." Recent positive developments include clinical evidence supporting Abbott's diabetes products and a marketing partnership with Real Madrid. However, Q4 revenue fell short of expectations, contributing to mixed analyst sentiment.</p>

Market Beat

Abbott Laboratories

SPDR S&P Health Equip

iShares Global Healthcare

Invesco Ltd. Boosts Holdings in Abbott Laboratories $ABT